Sissel Rodahl
Corporate Officer/Principal bei GENSIGHT BIOLOGICS S.A.
Profil
Sissel Rodahl is currently the Senior Vice President-Commercial Operations at Gensight Biologics SA since 2022.
Prior to this, she worked as Vice President at Novartis Gene Therapies, Inc. from 2018 to 2022.
She completed her graduate degree from the University of Oslo and her undergraduate degree from Engineering College.
Aktive Positionen von Sissel Rodahl
| Unternehmen | Position | Beginn |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Corporate Officer/Principal | 31.01.2022 |
Ehemalige bekannte Positionen von Sissel Rodahl
| Unternehmen | Position | Ende |
|---|---|---|
| AVEXIS INC | Corporate Officer/Principal | 01.02.2022 |
Ausbildung von Sissel Rodahl
| University of Oslo | Graduate Degree |
| Engineering College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
